1
|
Vecchio E, Marino R, Mimmi S, Canale C, Caiazza C, Arcucci A, Ruocco MR, Schiavone M, Santamaria G, Palmieri C, Iaccino E, Mallardo M, Quinto I, Fiume G. Enhanced pro-apoptotic activity of rituximab through IBTK silencing in non-Hodgkin lymphoma B-cells. Front Oncol 2024; 14:1339584. [PMID: 38371626 PMCID: PMC10869532 DOI: 10.3389/fonc.2024.1339584] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2023] [Accepted: 01/17/2024] [Indexed: 02/20/2024] Open
Abstract
Rituximab is a commonly used chemotherapeutic drug for patients with aggressive lymphomas, such as non-Hodgkin's lymphoma (NHL). Currently, the combination of Rituximab and chemotherapy (R-CHOP) stands as the most prevalent first-line therapy for NHL. Nevertheless, the development of new therapeutic approaches remains imperative. An increasing body of evidence highlights a novel role for IBTK in tumorigenesis and cancer growth. In this study, we aim to broaden our understanding of IBTK's function in B-lymphoma, with a particular focus on its impact on the expression of the oncogene MYC. Here, we assessed the effects of combining Rituximab with IBTK silencing on cell viability through cell cycle analysis and Annexin V assays in vitro. Furthermore, we leveraged the transplantability of Eμ-myc lymphomas to investigate whether the inhibition of IBTK could elicit anti-tumor effects in the treatment of lymphomas in vivo. Our data suggests that IBTK silencing may serve as an effective anti-tumor agent for aggressive B-Lymphomas, underscoring its role in promoting apoptosis when used in combination with Rituximab, both in in vitro and in vivo settings.
Collapse
Affiliation(s)
- Eleonora Vecchio
- Department of Experimental and Clinical Medicine, University Magna Græcia of Catanzaro, Catanzaro, Italy
| | - Rossana Marino
- Department of Molecular Medicine and Medical Biotechnology, University of Naples “Federico II”, Naples, Italy
| | - Selena Mimmi
- Department of Experimental and Clinical Medicine, University Magna Græcia of Catanzaro, Catanzaro, Italy
| | - Camilla Canale
- Department of Molecular Medicine and Medical Biotechnology, University of Naples “Federico II”, Naples, Italy
| | - Carmen Caiazza
- Department of Molecular Medicine and Medical Biotechnology, University of Naples “Federico II”, Naples, Italy
| | - Alessandro Arcucci
- Department of Public Health, University of Naples “Federico II”, Naples, Italy
| | - Maria Rosaria Ruocco
- Department of Molecular Medicine and Medical Biotechnology, University of Naples “Federico II”, Naples, Italy
| | - Marco Schiavone
- Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
| | - Gianluca Santamaria
- Department of Experimental and Clinical Medicine, University Magna Græcia of Catanzaro, Catanzaro, Italy
| | - Camillo Palmieri
- Department of Experimental and Clinical Medicine, University Magna Græcia of Catanzaro, Catanzaro, Italy
| | - Enrico Iaccino
- Department of Experimental and Clinical Medicine, University Magna Græcia of Catanzaro, Catanzaro, Italy
| | - Massimo Mallardo
- Department of Molecular Medicine and Medical Biotechnology, University of Naples “Federico II”, Naples, Italy
| | - Ileana Quinto
- Department of Experimental and Clinical Medicine, University Magna Græcia of Catanzaro, Catanzaro, Italy
| | - Giuseppe Fiume
- Department of Experimental and Clinical Medicine, University Magna Græcia of Catanzaro, Catanzaro, Italy
| |
Collapse
|
2
|
Vecchio E, Fiume G, Mignogna C, Iaccino E, Mimmi S, Maisano D, Trapasso F, Quinto I. IBTK Haploinsufficiency Affects the Tumor Microenvironment of Myc-Driven Lymphoma in E-myc Mice. Int J Mol Sci 2020; 21:E885. [PMID: 32019112 DOI: 10.3390/ijms21030885] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2019] [Revised: 01/27/2020] [Accepted: 01/28/2020] [Indexed: 02/07/2023] Open
Abstract
The tumor microenvironment is a dynamic and interactive supporting network of various components, including blood vessels, cytokines, chemokines, and immune cells, which sustain the tumor cell’s survival and growth. Murine models of lymphoma are useful to study tumor biology, the microenvironment, and mechanisms of response to therapy. Lymphomas are heterogeneous hematologic malignancies, and the complex microenvironment from which they arise and their multifaceted genetic basis represents a challenge for the generation and use of an appropriate murine model. So, it is important to choose the correct methodology. Recently, we supported the first evidence on the pro-oncogenic action of IBTK in Myc-driven B cell lymphomagenesis in mice, inhibiting apoptosis in the pre-cancerous stage. We used the transgenic Eμ-myc mouse model of non-Hodgkin’s lymphoma and Ibtk hemizygous mice to evaluate the tumor development of Myc-driven lymphoma. Here, we report that the allelic loss of Ibtk alters the immunophenotype of Myc-driven B cell lymphomas, increasing the rate of pre-B cells and affecting the tumor microenvironment in Eμ-myc mice. In particular, we observed enhanced tumor angiogenesis, increasing pro-angiogenic and lymphangiogenic factors, such as VEGF, MMP-9, CCL2, and VEGFD, and a significant recruitment of tumor-associated macrophages in lymphomas of Ibtk+/-Eμ-myc compared to Ibtk+/+Eμ-myc mice. In summary, these results indicate that IBTK haploinsufficiency promotes Myc tumor development by modifying the tumor microenvironment.
Collapse
|
3
|
Fiume G, Scialdone A, Rizzo F, De Filippo MR, Laudanna C, Albano F, Golino G, Vecchio E, Pontoriero M, Mimmi S, Ceglia S, Pisano A, Iaccino E, Palmieri C, Paduano S, Viglietto G, Weisz A, Scala G, Quinto I. IBTK Differently Modulates Gene Expression and RNA Splicing in HeLa and K562 Cells. Int J Mol Sci 2016; 17:ijms17111848. [PMID: 27827994 PMCID: PMC5133848 DOI: 10.3390/ijms17111848] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2016] [Revised: 10/21/2016] [Accepted: 10/31/2016] [Indexed: 01/04/2023] Open
Abstract
The IBTK gene encodes the major protein isoform IBTKα that was recently characterized as substrate receptor of Cul3-dependent E3 ligase, regulating ubiquitination coupled to proteasomal degradation of Pdcd4, an inhibitor of translation. Due to the presence of Ankyrin-BTB-RCC1 domains that mediate several protein-protein interactions, IBTKα could exert expanded regulatory roles, including interaction with transcription regulators. To verify the effects of IBTKα on gene expression, we analyzed HeLa and K562 cell transcriptomes by RNA-Sequencing before and after IBTK knock-down by shRNA transduction. In HeLa cells, 1285 (2.03%) of 63,128 mapped transcripts were differentially expressed in IBTK-shRNA-transduced cells, as compared to cells treated with control-shRNA, with 587 upregulated (45.7%) and 698 downregulated (54.3%) RNAs. In K562 cells, 1959 (3.1%) of 63128 mapped RNAs were differentially expressed in IBTK-shRNA-transduced cells, including 1053 upregulated (53.7%) and 906 downregulated (46.3%). Only 137 transcripts (0.22%) were commonly deregulated by IBTK silencing in both HeLa and K562 cells, indicating that most IBTKα effects on gene expression are cell type-specific. Based on gene ontology classification, the genes responsive to IBTK are involved in different biological processes, including in particular chromatin and nucleosomal organization, gene expression regulation, and cellular traffic and migration. In addition, IBTK RNA interference affected RNA maturation in both cell lines, as shown by the evidence of alternative 3′- and 5′-splicing, mutually exclusive exons, retained introns, and skipped exons. Altogether, these results indicate that IBTK differently modulates gene expression and RNA splicing in HeLa and K562 cells, demonstrating a novel biological role of this protein.
Collapse
Affiliation(s)
- Giuseppe Fiume
- Department of Experimental and Clinical Medicine, University 'Magna Graecia' of Catanzaro, Viale Europa (Località Germaneto), 88100 Catanzaro, Italy.
| | - Annarita Scialdone
- Department of Experimental and Clinical Medicine, University 'Magna Graecia' of Catanzaro, Viale Europa (Località Germaneto), 88100 Catanzaro, Italy.
| | - Francesca Rizzo
- Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'Schola Medica Salernitana', University of Salerno, via S. Allende 1, 84081 Baronissi, Italy.
| | - Maria Rosaria De Filippo
- Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'Schola Medica Salernitana', University of Salerno, via S. Allende 1, 84081 Baronissi, Italy.
| | - Carmelo Laudanna
- Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'Schola Medica Salernitana', University of Salerno, via S. Allende 1, 84081 Baronissi, Italy.
| | - Francesco Albano
- Department of Experimental and Clinical Medicine, University 'Magna Graecia' of Catanzaro, Viale Europa (Località Germaneto), 88100 Catanzaro, Italy.
| | - Gaetanina Golino
- Department of Experimental and Clinical Medicine, University 'Magna Graecia' of Catanzaro, Viale Europa (Località Germaneto), 88100 Catanzaro, Italy.
| | - Eleonora Vecchio
- Department of Experimental and Clinical Medicine, University 'Magna Graecia' of Catanzaro, Viale Europa (Località Germaneto), 88100 Catanzaro, Italy.
| | - Marilena Pontoriero
- Department of Experimental and Clinical Medicine, University 'Magna Graecia' of Catanzaro, Viale Europa (Località Germaneto), 88100 Catanzaro, Italy.
| | - Selena Mimmi
- Department of Experimental and Clinical Medicine, University 'Magna Graecia' of Catanzaro, Viale Europa (Località Germaneto), 88100 Catanzaro, Italy.
| | - Simona Ceglia
- Department of Experimental and Clinical Medicine, University 'Magna Graecia' of Catanzaro, Viale Europa (Località Germaneto), 88100 Catanzaro, Italy.
| | - Antonio Pisano
- Department of Experimental and Clinical Medicine, University 'Magna Graecia' of Catanzaro, Viale Europa (Località Germaneto), 88100 Catanzaro, Italy.
| | - Enrico Iaccino
- Department of Experimental and Clinical Medicine, University 'Magna Graecia' of Catanzaro, Viale Europa (Località Germaneto), 88100 Catanzaro, Italy.
| | - Camillo Palmieri
- Department of Experimental and Clinical Medicine, University 'Magna Graecia' of Catanzaro, Viale Europa (Località Germaneto), 88100 Catanzaro, Italy.
| | - Sergio Paduano
- Department of Health Sciences, University "Magna Graecia", 88100 Catanzaro, Italy.
| | - Giuseppe Viglietto
- Department of Experimental and Clinical Medicine, University 'Magna Graecia' of Catanzaro, Viale Europa (Località Germaneto), 88100 Catanzaro, Italy.
| | - Alessandro Weisz
- Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'Schola Medica Salernitana', University of Salerno, via S. Allende 1, 84081 Baronissi, Italy.
| | - Giuseppe Scala
- Department of Experimental and Clinical Medicine, University 'Magna Graecia' of Catanzaro, Viale Europa (Località Germaneto), 88100 Catanzaro, Italy.
| | - Ileana Quinto
- Department of Experimental and Clinical Medicine, University 'Magna Graecia' of Catanzaro, Viale Europa (Località Germaneto), 88100 Catanzaro, Italy.
| |
Collapse
|